Following this observation, Che et al. proposed TGF-β blockers as a possible treatment against severe COVID-19, reporting that the low concentration of TGF-ß induced an easy recovery, reducing the probability of pulmonary edema and pulmonary fibrosis [29]. Here, TGFB1 is linked to pulmonary fibrosis.